• Therapeutic use and formulation development of concentrated human serum albumin and salt-modified variants as clinical resuscitation and liver-disease therapies, reflecting early plasma protein therapeutics with real-world clinical deployment [1], [5], [9], [13], [16], [18].

• Biophysical and chemical characterization of albumin and fibrin systems, including osmotic behavior, thermal stability, salt/anion effects, and fibrin network morphologies, establishing foundational principles for safe handling and surgical biomaterials [3], [4], [6], [7], [11], [12], [14], [17].

• Immunological studies and immune interactions with plasma-derived products, documenting immune responses to albumin preparations and coagulation factors within the plasma fractionation program [1], [2], [4], [11], [16].

• Fibrin-based materials for hemostasis and surgical applications, including fibrin films, clots, foams, and thrombin interactions used in neurosurgery, renal surgery, burns, and surface treatments [7], [8], [12], [14], [17], [20].

• Clinical evaluation and measurement methodologies linked to plasma-based therapies, emphasizing shock treatment trials and physiological measurements alongside analytical chemistry approaches [13], [15], [16].